Advanced antisense therapies for postexposure protection against lethal filovirus infections.
Currently, no vaccines or therapeutics are licensed to counter Ebola or Marburg viruses, highly pathogenic filoviruses that are causative agents of viral hemorrhagic fever. Here we show that administration of positively charged phosphorodiamidate morpholino oligomers (PMOplus), delivered by various dosing strategies initiated 30-60 min after infection, protects>60% of rhesus monkeys against lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (MARV) infection. PMOplus may be useful for treating these and other highly pathogenic viruses in humans.
Warren
Travis K
TK
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Warfield
Kelly L
KL
Wells
Jay
J
Swenson
Dana L
DL
Donner
Kelly S
KS
Van Tongeren
Sean A
SA
Garza
Nicole L
NL
Dong
Lian
L
Mourich
Dan V
DV
Crumley
Stacy
S
Nichols
Donald K
DK
Iversen
Patrick L
PL
Bavari
Sina
S
D000818:Animals; D029043:Ebolavirus / Q000302:isolation & purification; D018702:Filoviridae Infections / Q000235:genetics* / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D019142:Hemorrhagic Fever, Ebola / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D008253:Macaca mulatta / Q000276:immunology; D008379:Marburg Virus Disease / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D029024:Marburgvirus / Q000302:isolation & purification; D011323:Primates; D012449:Safety; D014614:Vaccines, Synthetic / Q000627:therapeutic use*; D014765:Viral Vaccines / Q000627:therapeutic use*
D014614:Vaccines, Synthetic; D014765:Viral Vaccines